

The Medical Letter[®]

on Drugs and Therapeutics

Volume 66

Published online October 14, 2024

Online
Article

IN THIS ISSUE

Addendum: Effectiveness of mRNA COVID-19 Vaccines

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 66

Published online October 14, 2024

Online
Article

IN THIS ISSUE

Addendum: Effectiveness of mRNA COVID-19 Vaccines

Addendum: Effectiveness of mRNA COVID-19 Vaccines

A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (*Comirnaty*) and Moderna (*Spikevax*)¹ asked us to provide more information on the data that supported their licensure.

The vaccines were initially licensed by the FDA in 2021 (Pfizer) and 2022 (Moderna) based on the results of large, double-blind trials in SARS-CoV-2-naive adolescents and adults. Both vaccines significantly decreased the risk of symptomatic and severe SARS-CoV-2 infection compared to placebo.²⁻⁴ Issuance of the FDA Emergency Use Authorizations (EUAs) allowing use of the vaccines in younger children was initially based primarily on the results of immunogenicity studies. Titer levels of anti-SARS-CoV-2 neutralizing antibodies following vaccination were at least as high in persons 6 months through 11 years old as they were in comparator adult cohorts.^{5,6}

As with the influenza vaccine, efficacy trials are no longer required by the FDA for licensure of new COVID-19 vaccine formulations that only significantly differ from previous formulations in the virus strain that they target. Licensure is based on the immunogenicity, efficacy, and safety of previous formulations, and on the likelihood of the new formulations to protect against currently circulating SARS-CoV-2 variants.⁷⁻⁹

Observational studies suggest that all of the COVID-19 vaccine formulations available in the US in 2023-2024 were effective in reducing the incidence of COVID-19. In a case-control analysis of 14,860 COVID-19 nucleic acid amplification tests administered at community pharmacies to immunocompetent adults with COVID-like symptoms between September 2023 and May 2024, receipt of any 2023-2024 COVID-19 vaccine at least 7 days before the test was associated with a decreased incidence of SARS-CoV-2 infection. The estimated adjusted vaccine efficacy was 45%; it was 58% for infections likely caused by the XBB.1.5 variant, which the 2023-2024 vaccines targeted, and 37% for infections likely caused by the JN.1 variant.^{10,11}

In similar analyses of tests administered to adults with COVID-like illness within 10 days before or 3 days after an

emergency department/urgent care visit (n=245,504) or a hospitalization (n=77,103) between September 2023 and May 2024, receipt of any 2023-2024 COVID-19 vaccine at least 7 days before the test was associated with a decreased incidence of COVID-19 requiring an emergency department/urgent care visit (estimated adjusted vaccine efficacy 36%) or hospitalization (estimated adjusted vaccine efficacy 41%). Among hospitalized immunocompetent persons, the estimated adjusted vaccine efficacy against critical illness was 58%.^{10,12}

1. COVID-19 update: New Pfizer and Moderna vaccine formulations for 2024-2025. *Med Lett Drugs Ther* 2024; 66:151.
2. FP Polack et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; 383:2603.
3. LR Baden et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2021; 384:403.
4. K Ali et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. *N Engl J Med* 2021; 385:2241.
5. FDA. Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization (EUA) of Pfizer-BioNTech COVID-19 vaccine (2024-2025 formula), for 6 months through 11 years of age. August 22, 2024. Available at: <https://bit.ly/4g2dQxa>. Accessed September 26, 2024.
6. FDA. Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization (EUA) of Moderna COVID-19 vaccine (2024-2025 formula), for individuals 6 months through 11 years of age. August 2024. Available at: <https://bit.ly/3YZmmqo>. Accessed September 26, 2024.
7. FDA News Release. FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants. August 22, 2024. Available at: <https://bit.ly/3T3eGzP>. Accessed September 26, 2024.
8. FDA CBER. Summary minutes. 185th Vaccines and Related Biological Products Advisory Committee. June 5, 2024. Available at: <https://bit.ly/4enFzqm>. Accessed September 26, 2024.
9. COVID-19 Real-Time Learning Network. COVID-19 variant update. September 17, 2024. Available at: <https://bit.ly/3XslucR>. Accessed September 26, 2024.
10. R Link-Gelles. Effectiveness of COVID-19 (2023-2024 formula) vaccines. ACIP Meeting COVID-19 Vaccines. June 27, 2024. Available at: <https://bit.ly/3TGt41a>. Accessed September 26, 2024.
11. R Link-Gelles et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. *MMWR Morb Mortal Wkly Rep* 2024; 73:77.
12. J DeCuir et al. Interim effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024. *MMWR Morb Mortal Wkly Rep* 2024; 73:180.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:




To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2024. ISSN 0025-732X

